Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 3
1990 5
1991 2
1992 1
1993 1
1994 3
1995 1
1997 1
1998 1
1999 1
2001 1
2003 1
2004 1
2005 1
2006 1
2009 1
2010 1
2013 1
2014 1
2015 1
2017 2
2018 1
2019 2
2020 1
2021 2
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

37 results
Results by year
Filters applied: . Clear all
Page 1
Future Research Goals in Immunotherapy.
Hulett TW, Fox BA, Messenheimer DJ, Marwitz S, Moudgil T, Afentoulis ME, Wegman KW, Ballesteros-Merino C, Jensen SM. Hulett TW, et al. Among authors: moudgil t. Surg Oncol Clin N Am. 2019 Jul;28(3):505-518. doi: 10.1016/j.soc.2019.02.006. Epub 2019 Apr 12. Surg Oncol Clin N Am. 2019. PMID: 31079803 Review.
HDAC inhibition prevents transgene expression downregulation and loss-of-function in T-cell-receptor-transduced T cells.
Moore TV, Scurti GM, DeJong M, Wang SY, Dalheim AV, Wagner CR, Hutchens KA, Speiser JJ, Godellas CV, Fountain C, Fleser J, Moudgil T, Thomas M, Murray D, Curti BD, Clark JI, Fox BA, Nishimura MI. Moore TV, et al. Among authors: moudgil t. Mol Ther Oncolytics. 2021 Jan 26;20:352-363. doi: 10.1016/j.omto.2021.01.014. eCollection 2021 Mar 26. Mol Ther Oncolytics. 2021. PMID: 33614916 Free PMC article.
Signaling through OX40 enhances antitumor immunity.
Jensen SM, Maston LD, Gough MJ, Ruby CE, Redmond WL, Crittenden M, Li Y, Puri S, Poehlein CH, Morris N, Kovacsovics-Bankowski M, Moudgil T, Twitty C, Walker EB, Hu HM, Urba WJ, Weinberg AD, Curti B, Fox BA. Jensen SM, et al. Among authors: moudgil t. Semin Oncol. 2010 Oct;37(5):524-32. doi: 10.1053/j.seminoncol.2010.09.013. Semin Oncol. 2010. PMID: 21074068 Free PMC article. Review.
Cancer immunotherapy: the role regulatory T cells play and what can be done to overcome their inhibitory effects.
Petrausch U, Poehlein CH, Jensen SM, Twitty C, Thompson JA, Assmann I, Puri S, LaCelle MG, Moudgil T, Maston L, Friedman K, Church S, Cardenas E, Haley DP, Walker EB, Akporiaye E, Weinberg AD, Rosenheim S, Crocenzi TS, Hu HM, Curti BD, Urba WJ, Fox BA. Petrausch U, et al. Among authors: moudgil t. Curr Mol Med. 2009 Aug;9(6):673-82. doi: 10.2174/156652409788970670. Curr Mol Med. 2009. PMID: 19689294 Free PMC article. Review.
OX40 is a potent immune-stimulating target in late-stage cancer patients.
Curti BD, Kovacsovics-Bankowski M, Morris N, Walker E, Chisholm L, Floyd K, Walker J, Gonzalez I, Meeuwsen T, Fox BA, Moudgil T, Miller W, Haley D, Coffey T, Fisher B, Delanty-Miller L, Rymarchyk N, Kelly T, Crocenzi T, Bernstein E, Sanborn R, Urba WJ, Weinberg AD. Curti BD, et al. Among authors: moudgil t. Cancer Res. 2013 Dec 15;73(24):7189-7198. doi: 10.1158/0008-5472.CAN-12-4174. Epub 2013 Oct 31. Cancer Res. 2013. PMID: 24177180 Free PMC article. Clinical Trial.
Immunological and molecular analysis of the sentinel lymph node: a potential approach to predict outcome, tailor therapy, and optimize parameters for tumor vaccine development.
Meijer SL, Dols A, Hu HM, Jensen S, Poehlein CH, Chu Y, Winter H, Yamada J, Moudgil T, Wood WJ, Doran T, Justice L, Fisher B, Wisner P, Wood J, Vetto JT, Mehrotra R, Rosenheim S, Weinberg AD, Bright R, Walker E, Puri R, Smith JW 2nd, Urba WJ, Fox BA. Meijer SL, et al. Among authors: moudgil t. J Clin Pharmacol. 2001 Jul;41(S7):81S-94S. J Clin Pharmacol. 2001. PMID: 11452734 Review. No abstract available.
37 results